Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% After Analyst Upgrade

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report)'s share price traded up 7.1% on Tuesday after Jefferies Financial Group raised their price target on the stock from $16.00 to $19.00. Jefferies Financial Group currently has a buy rating on the stock. Arcutis Biotherapeutics traded as high as $15.25 and last traded at $15.40. 1,221,408 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 2,200,479 shares. The stock had previously closed at $14.38.

A number of other brokerages have also recently weighed in on ARQT. The Goldman Sachs Group boosted their price target on shares of Arcutis Biotherapeutics from $13.00 to $15.00 and gave the company a "neutral" rating in a research report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and issued a $19.00 target price on shares of Arcutis Biotherapeutics in a research report on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and set a $20.00 price target on shares of Arcutis Biotherapeutics in a research note on Wednesday, February 26th. Guggenheim reiterated a "buy" rating on shares of Arcutis Biotherapeutics in a research note on Monday, February 24th. Finally, Mizuho increased their price objective on Arcutis Biotherapeutics from $20.00 to $21.00 and gave the company an "outperform" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $18.80.

Insider Transactions at Arcutis Biotherapeutics

In related news, Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $13.00, for a total value of $130,000.00. Following the sale, the director now directly owns 131,944 shares in the company, valued at $1,715,272. The trade was a 7.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Todd Franklin Watanabe sold 15,000 shares of the company's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $15.17, for a total value of $227,550.00. Following the transaction, the insider now directly owns 823,430 shares in the company, valued at $12,491,433.10. This represents a 1.79 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,848 shares of company stock worth $797,648. Company insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On Arcutis Biotherapeutics

A number of large investors have recently made changes to their positions in the stock. Point72 DIFC Ltd acquired a new position in Arcutis Biotherapeutics during the third quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Arcutis Biotherapeutics in the 4th quarter worth approximately $34,000. Venturi Wealth Management LLC acquired a new stake in shares of Arcutis Biotherapeutics in the 4th quarter worth approximately $46,000. Erste Asset Management GmbH purchased a new position in Arcutis Biotherapeutics in the 3rd quarter valued at approximately $104,000. Finally, Victory Capital Management Inc. raised its holdings in Arcutis Biotherapeutics by 9.9% during the third quarter. Victory Capital Management Inc. now owns 12,843 shares of the company's stock worth $119,000 after purchasing an additional 1,155 shares during the last quarter.

Arcutis Biotherapeutics Stock Performance

The company has a debt-to-equity ratio of 0.67, a current ratio of 2.46 and a quick ratio of 2.38. The company has a market capitalization of $1.84 billion, a PE ratio of -8.65 and a beta of 1.48. The stock has a 50-day simple moving average of $13.45 and a 200 day simple moving average of $11.72.

Remove Ads

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.19. The business had revenue of $71.36 million for the quarter, compared to analyst estimates of $60.52 million. Arcutis Biotherapeutics had a negative net margin of 140.97% and a negative return on equity of 119.11%. Equities analysts anticipate that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current fiscal year.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.